Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Angle losses deepen on increased investment spend

Wednesday, 25th July 2018
Liquied biopsy company Angle posted a deeper annual loss, owing to planned investment in its offering.

Pre-tax losses for the year through April amounted to £7.6m, compared to losses of £6.3m a year earlier.

Angle said an FDA clinical study of 400 was in progress with four leading US cancer centres, targeted for completion this year.

'With two successful ovarian cancer studies, the initiation of our FDA clinical studies and three global healthcare companies secured as partners, Angle has established world-wide recognition and potential,' chairman Garth Selvey said.

'The acquisition of downstream analysis technology complements the Parsortix system and will, in time, allow us to offer our customers a full 'sample to answer' solution.'

'We continue to invest heavily to pursue FDA clearance for the Parsortix system as the first ever FDA cleared clinical device to harvest intact circulating tumour cells for analysis from patient blood.'

'Commencement of clinical trials at four prestigious US cancer centres marks a major step forward for the business.'

At 2:50pm: (LON:AGL) Angle PLC share price was -1.5p at 52.5p

Story provided by

Related Shares: Angle

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.